Evidence map›Paper›PMID 34597274›Full record

Trial reportThe Journal of clinical investigation2021

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.

Tomoko Nakanishi, Sara Pigazzini, Frauke Degenhardt, Mattia Cordioli, Guillaume Butler-Laporte, Douglas Maya-Miles, Luis Bujanda, Youssef Bouysran, Mari Ek Niemi, Adriana Palom and 39 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04316884 (Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19), which is not on this map. Cited by 74 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04316884 completednot on this map

Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19

TypeobservationalSponsorUppsala UniversityRan2020 to 2025Enrolled380ConditionsCOVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple, Septic Shock
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Advances in laboratory medicine · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors.

Tomoko NakanishiInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Sara PigazziniInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Frauke DegenhardtInstitute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
Mattia CordioliInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Guillaume Butler-LaporteCentre for Clinical Epidemiology, Department of Medicine, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Quebec, Canada.
Douglas Maya-MilesDigestive Diseases Unit, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.
Luis BujandaDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain.
Youssef BouysranCentre de Génétique Humaine, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Mari Ek NiemiInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Adriana PalomLiver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
David EllinghausInstitute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
Atlas KhanDivision of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Manuel Martínez-BuenoGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Selina Rolkernstitute of Human Genetics, University Hospital Bonn, Medical Faculty University of Bonn, Bonn, Germany.
Sara AmitranoGenetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
Luisa Roade TatoCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Francesca FavaGenetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
FinnGen
COVID-19 Host Genetics Initiative (HGI)
Christoph D SpinnerTechnical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, Munich, Germany.
Daniele PratiDepartment of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milano, Italy.
David BernardoCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Federico GarciaHospital Universitario Clinico San Cecilio, Granada, Spain.
Gilles DarcisUniversity of Liege, GIGA-Insitute, Liege, Belgium.
Israel Fernández-CadenasStroke Pharmacogenomics and Genetics Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Jan Cato HolterDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Jesus M BanalesDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain.
Robert FrithiofDepartment of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.
Krzysztof KirylukDivision of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Stefano DugaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Rosanna AsseltaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Alexandre C PereiraHeart Institute (InCor)/University São Paulo Medical School, São Paulo, Brazil.
Manuel Romero-GómezDigestive Diseases Unit, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.
Beatriz Nafría-JiménezOsakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Clinical Biochemistry Department, Sebastian, Spain.
Johannes R HovDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Isabelle MigeotteCentre de Génétique Humaine, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Alessandra RenieriGenetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
Anna M PlanasInstitute for Biomedical Research of Barcelona (IIBB), National Spanish Research Council (CSIC), Barcelona, Spain.
Kerstin U Ludwignstitute of Human Genetics, University Hospital Bonn, Medical Faculty University of Bonn, Bonn, Germany.
Maria ButiCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Souad RahmouniInstituto de Investigación Ibs.Granada, Granada, Spain.
Marta E Alarcón-RiquelmeGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Eva C SchulteInstitute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
Tom H KarlsenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Luca ValentiDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
Hugo ZebergDepartment of Neuroscience, Karolinska Institutet, Sweden.
J Brent RichardsDepartment of Human Genetics and.
Andrea GannaInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Predictive utility of polygenic risk scores for chronic kidney disease.K25DK128563 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KHAN, ATLAS · 2021 to 2025
$846k
NCATS NIH HHS UL1 TR001873NIDDK NIH HHS K25 DK128563
6 · The paper itself

Abstract

BackgroundThere is considerable variability in COVID-19 outcomes among younger adults, and some of this variation may be due to genetic predisposition.MethodsWe combined individual level data from 13,888 COVID-19 patients (n = 7185 hospitalized) from 17 cohorts in 9 countries to assess the association of the major common COVID-19 genetic risk factor (chromosome 3 locus tagged by rs10490770) with mortality, COVID-19-related complications, and laboratory values. We next performed metaanalyses using FinnGen and the Columbia University COVID-19 Biobank.ResultsWe found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (HR, 1.4; 95% CI, 1.2-1.7). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (OR, 2.1; 95% CI, 1.6-2.6), venous thromboembolism (OR, 1.7; 95% CI, 1.2-2.4), and hepatic injury (OR, 1.5; 95% CI, 1.2-2.0). Risk allele carriers age 60 years and younger had higher odds of death or severe respiratory failure (OR, 2.7; 95% CI, 1.8-3.9) compared with those of more than 60 years (OR, 1.5; 95% CI, 1.2-1.8; interaction, P = 0.038). Among individuals 60 years and younger who died or experienced severe respiratory failure, 32.3% were risk-variant carriers compared with 13.9% of those not experiencing these outcomes. This risk variant improved the prediction of death or severe respiratory failure similarly to, or better than, most established clinical risk factors.ConclusionsThe major common COVID-19 genetic risk factor is associated with increased risks of morbidity and mortality, which are more pronounced among individuals 60 years or younger. The effect was similar in magnitude and more common than most established clinical risk factors, suggesting potential implications for future clinical risk management.

Indexed as

AllelesCOVID-19Gene FrequencyGenetic LociPolymorphism, GeneticSARS-CoV-2AgedAged, 80 and overAge FactorsChromosomes, Human, Pair 3FemaleHumansMaleMiddle AgedPatient AcuityRisk FactorsCOVID-19GeneticsGenetic variation

Identifiers

PMID34597274
PMCPMC8631592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.